1.
Jain M, Crites MK, Rich P, Bajantri B. Malignant pleural mesothelioma: a comprehensive review. J Clin Med. 2024;13(19):5837. doi:10.3390/jcm 13195837
2.
Mutlu E, Inanc M. Prognostic significance of inflammation scores in malignant mesothelioma. Eur Rev Med Pharmacol Sci. 2024;28(6):2340-2350. doi:10.26355/eurrev_202403_35741
3.
Yamagishi T, Fujimoto N, Nishi H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90(1):111-117. doi:10.1016/j.lungcan. 2015.07.014
4.
Ozyurek BA, Ozdemirel TS, Ozden SB, et al. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer? Clin Respir J. 2018;12(6):2013-2019. doi:10. 1111/crj.12768
5.
Karakaya S, Karadağ İ, Dogan M et al. Potential novel prognostic factors in malign mesothelioma: systemic inflammatory indices (SII) & albumin-to-globulin ratio (AGR). Acta Haematol Oncol Turc. 2021; 54(3):358-366. doi:10.5505/aot.2021.58815
6.
Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6(1):23893.
7.
Gong C, Yu X, Zhang W, et al. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. J Nanobiotechnology. 2021;19(1):58. doi:10.1186/s12951-021-00805-8
8.
Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6(38):41370-41382. doi:10.18632/oncotarget.5629
9.
Kılınç CY, Gürsan O, Acan A, Gultac E. Prognostic nutritional index predicts perioperative adverse events in patients undergoing hemiarthroplasty after a hip fracture. J Exp Clin Med. 2022;39(1):24-27.
10.
Vogl M, Rosenmayr A, Bohanes T, et al. Biomarkers for malignant pleural mesothelioma-a novel view on inflammation. Cancers (Basel). 2021;13(4):658-658. doi:10.3390/cancers13040658
11.
Chen N, Liu S, Huang L, et al. Prognostic significance of neutrophil- to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis. Oncotarget. 2017;8(34):57460-57469.
12.
Yin W, Zheng G, Yang K, Song H, Liang Y. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. World J Surg Oncol. 2018;16(1):44. doi: 10.1186/s12957-018-1350-5
13.
Alpert N, van Gerwen M,Taioli E. Epidemiology of mesothelioma in the 21<sup>st</sup> century in Europe and the United States, 40 years after restricted/ banned asbestos use. Transl Lung Cancer Res. 2020;9(suppl 1):S28-S38.
14.
Chen T, Sun X-M, Wu L. High time for complete ban on asbestos use in developing countries. JAMA Oncol. 2019;5(6):779-780.
15.
Taioli E, Wolf A, Alpert N, Rosenthal D, Flores R. Malignant pleural mesothelioma characteristics and outcomes: a SEER-Medicare analysis. J Surg Oncol. 2023;128(1):134-141. doi:10.1002/jso.27243
16.
Tural Onur S, Sokucu SN, Dalar L, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag. 2016;12: 651-656.
17.
Cihan YB, Ozturk A, Mutlu H. Relationship between prognosis and neutrophil: lymphocyte and platelet lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev. 2014;15(5): 2061-2067. doi:10.7314/apjcp.2014.15.5.2061
18.
Yao ZH, Tian GY, Yang SX, et al. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. Tumour Biol. 2014;35(7):6839-6845. doi:10.1007/s13277-014-1938-5
19.
Yao ZH, Tian GY, Wan YY, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139(12):2117-2123. doi:10.1007/s00432-013-1523-0
20.
Ebinç S, Oruç Z, Kalkan Z, et al. Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. Turk Gogus Kalp Damar Cerrahisi Derg. 2023;31(1):105-115.
21.
Dogan M, Utkan G, Hocazade C, et al. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. Med Oncol. 2014; 31(10): 232.